Incidence of SARS-CoV-2 Infection, Emergency Department Visits, and Hospitalizations Because of COVID-19 Among Persons Aged ≥12 Years, by COVID-19 Vaccination Status - Oregon and Washington, July 4-September 25, 2021
- PMID: 34793417
- PMCID: PMC8601415
- DOI: 10.15585/mmwr.mm7046a4
Incidence of SARS-CoV-2 Infection, Emergency Department Visits, and Hospitalizations Because of COVID-19 Among Persons Aged ≥12 Years, by COVID-19 Vaccination Status - Oregon and Washington, July 4-September 25, 2021
Abstract
Population-based rates of infection with SARS-CoV-2 (the virus that causes COVID-19) and related health care utilization help determine estimates of COVID-19 vaccine effectiveness and averted illnesses, especially since the SARS-CoV-2 B.1.617.2 (Delta) variant began circulating in June 2021. Among members aged ≥12 years of a large integrated health care delivery system in Oregon and Washington, incidence of laboratory-confirmed SARS-CoV-2 infection, emergency department (ED) visits, and hospitalizations were calculated by COVID-19 vaccination status, vaccine product, age, race, and ethnicity. Infection after full vaccination was defined as a positive SARS-CoV-2 molecular test result ≥14 days after completion of an authorized COVID-19 vaccination series.* During the July-September 2021 surveillance period, SARS-CoV-2 infection occurred among 4,146 of 137,616 unvaccinated persons (30.1 per 1,000 persons) and 3,009 of 344,848 fully vaccinated persons (8.7 per 1,000). Incidence was higher among unvaccinated persons than among vaccinated persons across all demographic strata. Unvaccinated persons with SARS-CoV-2 infection were more than twice as likely to receive ED care (18.5%) or to be hospitalized (9.0%) than were vaccinated persons with COVID-19 (8.1% and 3.9%, respectively). The crude mortality rate was also higher among unvaccinated patients (0.43 per 1,000) than in fully vaccinated patients (0.06 per 1,000). These data support CDC recommendations for COVID-19 vaccination, including additional and booster doses, to protect individual persons and communities against COVID-19, including illness and hospitalization caused by the Delta variant (1).
Conflict of interest statement
All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Allison L. Naleway reported institutional funding from Pfizer for a meningococcal B vaccine study and Vir Biotechnology for an influenza vaccine study unrelated to the submitted work. Michelle L. Henninger reports institutional support from the Garfield Memorial Fund. No other potential conflicts of interest were disclosed.
References
-
- CDC. ACIP vaccine recommendations and guidelines. Atlanta, GA: US Department of Health and Human Services, CDC; 2021. Accessed November 15, 2021. https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/covid-19.html
-
- CDC. COVID data tracker. Atlanta, GA: US Department of Health and Human Services, CDC; 2021. Accessed November 15, 2021. https://covid.cdc.gov/covid-data-tracker/#datatracker-home
-
- CDC. Delta variant: what we know about the science. Atlanta, GA: US Department of Health and Human Services, CDC; 2021. Accessed October 27, 2021. https://www.cdc.gov/coronavirus/2019-ncov/variants/delta-variant.html
-
- CDC. COVID-19 data tracker. COVID-19 vaccinations in the United States. Atlanta, GA: US Department of Health and Human Services, CDC; 2021. Accessed November 15, 2021. https://covid.cdc.gov/covid-data-tracker/#vaccinations_vacc-total-admin-...
-
- COVID-19 Treatment Guidelines Panel. Coronavirus disease 2019 (COVID-19) treatment guidelines. Bethesda, MD: US Department of Health and Human Services, National Institutes of Health; 2021. Accessed October 27, 2021. https://www.covid19treatmentguidelines.nih.gov/
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
